Spectrum of Oncogenic Driver Mutations in Lung Adenocarcinomas from East Asian Never Smokers

Comparable rate of EGFR kinase domain mutation in lung adenocarcinomas from Chinese male and female never-smokers

(2010) Yi-hua Sun et al.   ACTA PHARMACOLOGICA SINICA

Cancer Statistics, 2010

(2010) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Lung Adenocarcinoma From East Asian Never-Smokers Is a Disease Largely Defined by Targetable Oncogenic Mutant Kinases

(2010) Yihua Sun et al.   JOURNAL OF CLINICAL ONCOLOGY

Neratinib, an Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor: Results of a Phase II Trial in Patients With Advanced Non–Small-Cell Lung Cancer

(2010) Lecia V. Sequist et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Trial of the Irreversible EGFR and HER2 Kinase Inhibitor BIBW 2992 in Patients With Advanced Solid Tumors

(2010) Timothy A. Yap et al.   JOURNAL OF CLINICAL ONCOLOGY

Association Between Age at Diagnosis and the Presence of EGFR Mutations in Female Patients with Resected Non-small Cell Lung Cancer

(2010) Yoon Hee Choi et al.   Journal of Thoracic Oncology

KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer

(2009) K. Takeuchi et al.   CLINICAL CANCER RESEARCH

Somatic mutations affect key pathways in lung adenocarcinoma

(2008) Li Ding et al.   NATURE

Gene expression–based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study

(2008) Kerby Shedden et al.   NATURE MEDICINE

Lung Cancer Occurrence in Never-Smokers: An Analysis of 13 Cohorts and 22 Cancer Registry Studies

(2008) Michael J Thun et al.   PLOS MEDICINE